<DOC>
	<DOCNO>NCT00505687</DOCNO>
	<brief_summary>The objective open-label extension ass safety tolerability long-term treatment rotigotine subject idiopathic PD .</brief_summary>
	<brief_title>An Open-Label Extension Trial Assess Safety Tolerability Long Term Treatment Rotigotine Subjects With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description>This open-label extension open-label trial SP824 ( NCT00242008 ) , SP825 ( NCT00243971 ) , SP826 ( NCT00243945 ) assess efficacy safety tolerability rotigotine subject idiopathic Parkinson 's Disease .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects complete treatment one SP824 ( NCT00242008 ) , SP825 ( NCT00243971 ) , SP826 ( NCT00243945 ) trial Subjects ongoing serious adverse event previous OLE trial assess related study medication</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NeuproÂ®</keyword>
</DOC>